Methylation silencing of TGF-β receptor type II is involved in malignant transformation of esophageal squamous cell carcinoma

Clin Epigenetics. 2020 Feb 11;12(1):25. doi: 10.1186/s13148-020-0819-6.

Abstract

Background: Although massive studies have been conducted to investigate the mechanisms of esophageal squamous cell carcinoma (ESCC) carcinogenesis, the understanding of molecular alterations during the malignant transformation of epithelial dysplasia is still lacking, especially regarding epigenetic changes.

Results: To better characterize the methylation changes during the malignant transformation of epithelial dysplasia, a whole-genome bisulfite sequencing analysis was performed on a series of tumor, dysplastic, and non-neoplastic epithelial tissue samples from esophageal squamous cell carcinoma (ESCC) patients. Promoter hypermethylation in TGF-β receptor type II (TGFBR2), an important mediator of TGF-β signaling, was identified. Further, we evaluated the methylation and expression of TGFBR2 in tumor samples through The Cancer Genome Atlas multiplatform data as well as immunohistochemistry. Moreover, treatment of ESCC cell lines with5-Aza-2'-deoxycytidine, a DNA methyltransferase inhibitor, reactivated the expression of TGFBR2. The lentiviral mediating the overexpression of TGFBR2 inhibited the proliferation of ESCC cell line by inducing cell cycle G2/M arrest. Furthermore, the overexpression of TGFBR2 inhibited the tumor growth obviously in vivo.

Conclusions: The characterization of methylation silencing of TGFBR2 in ESCC will enable us to further explore whether this epigenetic change could be considered as a predictor of malignant transformation in esophageal epithelial dysplasia and whether use of a TGFBR2 agonist may lead to a new therapeutic strategy in patients with ESCC.

Keywords: Cancer diagnosis; Esophageal squamous cell carcinoma; Methylation changes; TGFBR2; Treatment; Whole genome bisulfite sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis / drug effects
  • Carcinogenesis / genetics
  • DNA Methylation / drug effects*
  • Decitabine / therapeutic use
  • Down-Regulation
  • Enzyme Inhibitors / therapeutic use
  • Epigenesis, Genetic / drug effects*
  • Esophageal Neoplasms / pathology*
  • Esophageal Squamous Cell Carcinoma / drug therapy
  • Esophageal Squamous Cell Carcinoma / genetics*
  • Esophageal Squamous Cell Carcinoma / pathology
  • Exome Sequencing / methods
  • Female
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Gene Silencing / drug effects
  • Heterografts
  • Humans
  • Mice
  • Mice, Inbred BALB C / genetics
  • Promoter Regions, Genetic / drug effects
  • Receptor, Transforming Growth Factor-beta Type II / agonists
  • Receptor, Transforming Growth Factor-beta Type II / genetics*
  • Receptor, Transforming Growth Factor-beta Type II / metabolism
  • Receptor, Transforming Growth Factor-beta Type II / therapeutic use

Substances

  • Enzyme Inhibitors
  • Decitabine
  • Receptor, Transforming Growth Factor-beta Type II
  • TGFBR2 protein, human